Neuphoria Therapeutics (NEUP) Current Leases (2020 - 2025)
Neuphoria Therapeutics (NEUP) reported Current Leases of $85210.0 for Q3 2025, down 34.39% year-over-year from $129881.0 in Q3 2024, and down 26.74% on a QoQ basis from $116314.0 in Q2 2025.
Neuphoria Therapeutics (NEUP) has 6 years of Current Leases data on file, last reported at $85210.0 in Q3 2025.
- Quarterly Current Leases fell 34.39% year-over-year to $85210.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $85210.0 (down 34.39% YoY) and the FY2025 annual result came in at $116314.0, down 4.65% from the prior year.
- Current Leases fell to $85210.0 in Q3 2025 per NEUP's latest filing, from $116314.0 in the prior quarter.
- Across five years, Current Leases topped out at $134157.5 in Q2 2021 and bottomed at $85210.0 in Q3 2025.
- The 5-year median for Current Leases is $118492.0 (2024), against an average of $117474.0.
- The widest annual swing landed in 2021, when Current Leases sank 73.34%; it then climbed 6.22% in 2024.
- Tracing NEUP's Current Leases over 5 years: stood at $134157.5 in 2021, then declined by 14.55% to $114631.6 in 2022, then advanced by 0.19% to $114851.7 in 2023, then climbed by 3.17% to $118492.0 in 2024, then slipped by 28.09% to $85210.0 in 2025.
- Per Business Quant, the three latest NEUP Current Leases figures stand at $85210.0 (Q3 2025), $116314.0 (Q2 2025), and $121738.0 (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 83,991.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 720.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 45.66 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 85,210.00 |
| Jun 30, 2025 | 116,314.00 |
| Mar 31, 2025 | 121,738.00 |
| Dec 31, 2024 | 118,492.00 |
| Sep 30, 2024 | 129,881.00 |
| Jun 30, 2024 | 121,990.00 |
| Jun 30, 2023 | 114,851.73 |
| Jun 30, 2022 | 114,631.58 |
| Jun 30, 2021 | 134,157.47 |
| Jun 30, 2020 | 503,173.62 |